Design and synthesis of deuterium-labeled vorapaxar / 中国药科大学学报
Journal of China Pharmaceutical University
;
(6): 295-300, 2018.
Artículo
en Chino
| WPRIM
| ID: wpr-704338
ABSTRACT
Vorapaxar,a novel antagonist of the protease-activated receptor 1 (PAR-1 ),can inhibit the clotting process. Deuterium-labeled vorapaxar was required for the analysis of clinical sample as an internal stand-ard. Starting for unlabeled vorapaxar,four-step reactions including hydrolysis,condensation,transesterification and hydrogen-deuterium exchange were carried out to synthesize [D8]vorapaxar effectively for the first time. All intermediates and final products were confirmed by NMR and high resolution mass spectrometry (HRMS).Impor-tantly,the prepared [D8]vorapaxar could meet the requirements of sample analysis as the internal standard.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Journal of China Pharmaceutical University
Año:
2018
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS